Special Issue "Molecules against Alzheimer II"
Deadline for manuscript submissions: closed (30 April 2019).
Interests: multitarget anti-Alzheimer agents; hybrid compounds; cholinesterase inhibitors; amyloid anti-aggregating compounds; BACE-1 inhibitors; antiprotozoan compounds
Special Issues and Collections in MDPI journals
Special Issue in Molecules: Multicomponent Reaction-Based Synthesis of Bioactive Molecules
Special Issue in Molecules: Emerging Drug Discovery Approaches against Infectious Diseases
Special Issue in Molecules: Present and Future of Medicinal Chemistry Research: A Young Researchers’ Perspective
Special Issue in Molecules: Facing Novel Challenges in Drug Discovery
Topical Collection in Molecules: Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
Special Issue in Molecules: Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 2020
Special Issue in Molecules: Feature Papers to Celebrate Molecules Reaches 20,000 Articles Milestone
Special Issue in Molecules: 25th Anniversary of Molecules—Recent Advances in Medicinal Chemistry
Interests: hybrid compounds; multifunctional cholinesterase inhibitors; cannabinoid and other GPCR ligands; natural products
Special Issues and Collections in MDPI journals
The prevalence, mortality and economic figures associated with Alzheimer’s disease (AD) are continuously beating the most worrisome predictions. The ever-increasing impact of AD is leading to unbearable suffering for patients, relatives and caregivers, and will put health systems and national economies worldwide at unmanageable risk if drug development efforts are not successful. The social awareness of the huge burden of AD and the tremendous decades-long research efforts to delineate their pathogenic mechanisms and develop efficient therapies have not corresponded with the discovery of new drugs that have proven capable of halting or even just slowing down the neurodegenerative processes occurring in AD. Indeed, AD is one of the therapeutic areas with the highest attrition rates in clinical trials. However, this should not discourage us from maintaining our intensive research endeavors, rather the opposite. In this light, the best-established (but so far unproductive) working hypotheses on the pathogenic mechanisms of AD are being continuously revisited and new promising hypotheses are being drawn up, thereby providing very valuable clues for the development of the long-sought-after disease-modifying drugs.
Following the successful first edition, this Special Issue aims to gather recent medicinal chemistry works focused on the discovery of novel biological targets, diagnostic tools and drug candidates and the application of innovative CNS drug delivery systems and therapeutic approaches that can improve the early detection and treatment of AD. We welcome original articles and short communications as well as a limited number of review articles on these topics. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on the Special Issue website.
Prof. Dr. Diego Muñoz-Torrero
Prof. Dr. Michael Decker
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s disease
- drug discovery
- drug design
- drug synthesis
- disease-modifying agents
- neuroprotective compounds
- cognition enhancing agents
- diagnostic agents (like PET or SPECT)